One of the most common points of confusion in product development is figuring out what, exactly, your product is from a regulatory standpoint. Not in terms of what it does for the consumer, but how the FDA classifies it. A wipe that kills bacteria on a wound could be an OTC drug, a medical device, or a surface disinfectant, depending on how it's formulated, labeled, and marketed. Getting this wrong early in development is expensive.
This post walks through the three main classifications brands most often confuse, what drives the distinction, and where the key regulatory frameworks live.
Your Label Is the Starting Point
FDA classification follows the claim, not the product form. A wipe is just a substrate. What matters is what you say it does.
If your product claims to treat, cure, mitigate, or prevent disease or a bodily condition in humans, it's likely a drug. If it works mechanically or physically (rather than chemically or pharmacologically), it may be a medical device. If it kills microorganisms on non-living surfaces, it's likely a pesticide, regulated by the EPA under FIFRA, not the FDA at all.
So the same gauze pad, depending on the claim printed on the box, could fall under three entirely different regulatory regimes. Brands frequently underestimate how much the label language drives compliance obligations.
OTC Drugs: The Monograph System
Most OTC drugs in the US are regulated through the FDA's monograph system. A monograph is essentially a published rulebook for a specific drug category. It specifies which active ingredients are permitted, at what concentrations, for which indications, and under what labeling conditions. If your product stays within a monograph, you don't need pre-market approval. You formulate to the monograph, label accordingly, and manufacture to GMP standards.
A few monographs that come up frequently in personal care and consumer health development:
Topical Antiseptics (First Aid Antiseptic Monograph) This covers products that reduce bacteria on skin to help prevent infection in minor cuts, scrapes, and burns. Permitted active ingredients include benzalkonium chloride (verify permitted concentrations against the current FDA administrative order, as ranges vary by product form and the applicable order, OTC000005 or its successor, should be the reference point rather than any historically cited figure), povidone-iodine (the monograph specifies permitted concentrations in terms of available iodine content rather than total povidone-iodine percentage; verify the applicable range against the current order before formulating), and hydrogen peroxide (historically cited at 3%, though its current GRASE status under the updated administrative order framework should be confirmed before formulating, as the post does not flag this uncertainty the way it does for other actives). If you're formulating a wound-care wipe that makes a first aid antiseptic claim, this is your monograph. Crucially, this covers skin, not surfaces. Claiming the product kills bacteria on a countertop takes you out of OTC drug territory entirely and into EPA/disinfectant regulation.
External Analgesics Products claiming to relieve minor pain topically, including lidocaine, menthol, and camphor formulations, fall here. Concentrations are tightly specified. Menthol, for example, has historically been listed at 1.25–16% when used as a counterirritant (producing that cooling or tingling sensation); for other indications such as antipruritic use, different concentration ranges apply. Verify this range against the current applicable OTC monograph administrative order before formulating, as monograph orders can be updated. The distinction between a cosmetic that "soothes" and an OTC drug that "relieves pain" comes down to label language.
Skin Protectants Petrolatum, zinc oxide, dimethicone, and a handful of other ingredients are approved under the skin protectant monograph. This one matters for brands in wound care, diaper and incontinence products, and barrier creams. Zinc oxide has historically been listed at 1–25% as a skin protectant; confirm this range against the current administrative order before formulating. Push the zinc oxide claim toward sun protection and you're now in the sunscreen monograph instead.
Sunscreens Probably the most complex of the commonly used monographs. Active ingredients, permitted concentrations, required SPF testing, and labeling requirements are all specified. The FDA has been revisiting sunscreen monograph requirements in recent years, and some UV filters widely used in European formulations remain under review for US marketing. Brands sourcing cosmetics contract manufacturer options for sunscreen products need to ensure their manufacturer is current on these requirements.
Acne Products Salicylic acid (0.5–2%) is consistent with the acne monograph. Benzoyl peroxide has a more complex regulatory history: FDA issued a proposed order in 2021 with updated conditions, and the commonly cited range of 2.5–10% should be confirmed against the most current FDA order before formulating, as requirements may have evolved. Any acne product making OTC drug claims needs to follow the current applicable framework precisely.
The OTC Reform Act: What Changed in 2020
The CARES Act of 2020 significantly restructured how OTC monograph products are governed. Previously, the system operated through informal guidance and proposed rules. Now, monographs are established through administrative orders, which means they carry the force of law and can be updated more efficiently. The FDA can issue an OTC Monograph Order Request (OMOR) to add or modify conditions.
For brands in development, the practical implication is that the regulatory landscape for OTC monograph products is more dynamic than it used to be. A formulation that was clearly compliant several years ago should be reviewed against current order status. This is particularly relevant for hand sanitizer actives (triclosan and triclocarban are no longer GRAS/GRAE) and certain sunscreen filters still pending review.
Medical Devices: When the Mechanism Is Physical
A product is a medical device if it achieves its intended purpose through mechanical, structural, or physical means rather than chemical action. Wound dressings are a good illustration. A bandage that simply covers a wound and provides a physical barrier is a medical device. A bandage that contains an active ingredient to reduce infection risk is a drug, or a drug-device combination product.
Device classification runs from Class I (lowest risk, general controls) through Class III (highest risk, pre-market approval required). Most wound care and first aid products are Class I or II. Class II products typically require a 510(k) submission, demonstrating that the device is substantially equivalent to a legally marketed predicate device.
For nonwovens-based products, bandages, dressings, and incontinence items, the device vs. drug question often comes down to whether any active ingredient is present and what claims are made. A hydrocolloid wound dressing with no active drug, making only physical performance claims, is a device. Add silver ions with an antimicrobial claim and you may have a combination product, which triggers a more complex regulatory pathway.
Surface Disinfectants: A Completely Different Framework
If your product is intended to kill or reduce microorganisms on surfaces rather than skin or wounds, you're working with the EPA, not the FDA. Surface disinfectants, sanitizers, and antimicrobial wipes intended for use on environmental surfaces (counters, medical equipment, hard surfaces) are regulated as pesticides under FIFRA.
EPA registration requires efficacy testing against specific organisms listed on the label, and the label itself is a legally binding document. Changing a claim, adding a pathogen to the kill list, or modifying the formulation after registration requires EPA review.
This distinction catches brands off guard more than almost any other regulatory issue. A client formulating an antimicrobial wipe, say, a witch hazel-based wipe intended for wound cleansing, needs to be precise about whether the intended use is on skin or on surfaces. Those are two completely different regulatory pipelines, with different testing requirements, different labeling frameworks, and different registration or compliance processes.
Where Products Fall Between Categories
Combination products and dual-use products are common in consumer health, and they add complexity. The FDA's Office of Combination Products (OCP) has jurisdiction over products that combine drug and device components, or drug and biologic components. If you're developing something like a medicated wound dressing, a drug-eluting bandage, or a device with an integral antimicrobial coating, combination product classification should be addressed early. The primary mode of action typically determines which FDA center leads the review.
Crown Abbey works with brands on exactly this kind of early-stage regulatory mapping. Before committing to a formulation approach, it's worth understanding which classification you're aiming for and whether your label claims, active ingredients, and intended use are aligned with that classification. Getting this right at the concept stage is considerably less painful than discovering a misclassification after stability testing is complete.
Practical Takeaways for Brands in Development
A few things worth keeping in mind as you move through early development:
Claims drive classification. Write your intended label copy early and review it against the relevant monograph or device classification. Don't finalize a formulation without knowing what claims it needs to support.
The monograph tells you the rules. If you're planning an OTC drug product in an established category, read the current monograph carefully. Active ingredient identity, concentration range, permitted indications, and required label language are all specified. Your formulator and your regulatory consultant both need to work from the same document.
Manufacturing requirements differ. OTC drugs must be manufactured under 21 CFR Parts 210 and 211 (pharmaceutical GMP). Medical devices have their own quality system requirements under 21 CFR Part 820. Cosmetics follow GMP guidelines like ISO 22716. If you're sourcing manufacturing, the facility needs to be qualified for the right category.
EPA-regulated products need separate planning. If any version of your product concept involves surface disinfection claims, get EPA registration requirements into your project timeline from day one. The timeline for EPA review is separate from, and often longer than, FDA OTC pathways.
Each of these categories has its own internal logic, and the confusion usually comes from approaching product development from the consumer experience outward rather than from the regulatory classification inward. Both perspectives matter, but starting with classification is what keeps development on track.
If you're working through classification questions on a new product concept, Crown Abbey can help map the regulatory landscape before development goes too far. Reach out to start the conversation.
← Back to Blog